Form 4: INSMED CEO Lewis Sells Shares After Option Exercise
Insider Transaction Report
INSMED Inc.'s Chair and CEO, William Lewis, exercised stock options and subsequently sold a portion of his common stock holdings under a pre-arranged 10b5-1 trading plan.
Summary
- William Lewis, Chair and CEO of INSMED Inc., reported transactions on December 4, 2025, involving the exercise of stock options and subsequent sale of common stock.
- Lewis exercised options to acquire 6,259 shares of common stock at an exercise price of $30.46 per share and 4,440 shares at an exercise price of $17.16 per share.
- Concurrently, Lewis sold a total of 10,699 shares of common stock in multiple transactions at weighted average sales prices ranging from $204.62 to $207.42 per share.
- All reported transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Lewis on September 4, 2025.
- Following these transactions, Lewis directly beneficially owns 303,911 shares of common stock.
- Indirect beneficial ownership includes 233,924 shares held by the Katie Procter Dynasty Trust and 50,500 shares held by the William Lewis Family Legacy Trust.
- Lewis retains 93,886 stock options with an exercise price of $30.46 and 66,600 stock options with an exercise price of $17.16, all of which are currently exercisable.
Sentiment
Score: 5
Explanation: The transactions are part of a pre-arranged 10b5-1 trading plan, which typically indicates a neutral sentiment as it's not based on immediate market timing or new information.
Positives
- The exercise of stock options at significantly lower prices ($30.46 and $17.16) compared to the sale prices (ranging from $204.62 to $207.42) indicates a substantial personal gain for the insider.
- The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which suggests a planned liquidity event rather than a reaction to immediate negative company news, enhancing transparency.
Negatives
- The transactions resulted in a net reduction of 10,699 shares in William Lewis's direct beneficial ownership of INSMED Inc. common stock following the option exercises and sales.
Future Outlook
NA
Industry Context
NA
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Policy/Plan | Transactions executed under a Rule 10b5-1 trading plan adopted on September 4, 2025, demonstrating adherence to pre-arranged trading protocols for insiders. | September 4, 2025 | Enhances transparency and reduces the perception of opportunistic insider trading, aligning with best practices for corporate governance regarding executive stock transactions. |
Stakeholder Impact
- Shareholders: The sale of shares by the CEO, while pre-planned, results in a reduction of his direct equity exposure, which could be viewed neutrally to slightly negatively depending on individual investor interpretation.
- Employees, Customers, Suppliers, Creditors: No direct impact from this insider trading report.
Key Dates
| Date | Description |
|---|---|
| September 4, 2025 | Adoption date of the Rule 10b5-1 trading plan by William Lewis. |
| December 4, 2025 | Date of stock option exercises and common stock sales by William Lewis. |
| May 17, 2027 | Expiration date for stock options with an exercise price of $17.16. |
| January 4, 2028 | Expiration date for stock options with an exercise price of $30.46. |
Keywords
INSMED Inc, INSM, William Lewis, Insider Trading, Form 4, Stock Options, Share Sale, 10b5-1 Plan, CEO, Director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.